EXAS Form 144: Insider to sell 1,500 vested shares for $90,000
Rhea-AI Filing Summary
Exact Sciences (EXAS) reported a proposed sale of 1,500 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $90,000. The shares represent a small fraction of the company's outstanding common stock of 189,319,110 shares. The filer acquired these shares on 02/23/2022 through restricted stock vesting and the transaction is classified as compensation. The planned sale date is 10/09/2025 on NASDAQ. No other sales by the filer in the past three months were reported, and the filer certifies they are not aware of undisclosed material adverse information at the time of the notice.
Positive
- Securities were acquired via restricted stock vesting, indicating the sale is monetization of compensation rather than a new short position
- No other sales in the past three months were reported for the filer, suggesting limited recent insider sell activity
Negative
- Insider plans to sell 1,500 shares on 10/09/2025, which may be perceived negatively by some investors despite small size
Insights
Small insider sale tied to vested restricted stock; limited market impact.
The notice shows an insider plans to sell 1,500 shares acquired on 02/23/2022 via restricted stock vesting, valued at $90,000. Because these shares were compensation, the sale appears to be routine monetization of vested equity rather than a position change tied to new information.
The sale represents roughly 0.00079% of the reported 189,319,110 shares outstanding, so direct dilution or price pressure is expected to be negligible. Watch the actual trade execution on 10/09/2025 for timing concentration or multiple related filings that could indicate larger insider activity within the same window.
FAQ
What insider sale did Exact Sciences (EXAS) report in this Form 144?
Did the filer report any other securities sold in the past three months?
Who is the broker handling the sale?